Table 1.
Patient Characteristics and Global Physician Assessment with Use of Type 2-Targeted Biologics
| ID# | Age | Sex | Race | Smoking history | Allergic rhinitis (allergen sensitization) | Asthma controller medications | CRS | Asthma | FEV1 baseline % predicted | lgE(kU/L) | AEC (K/uL) | Biologic | Duration on biologic (months) | Global physician assessment⇞ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 73 | F | Asian | Never | Yes (tree, grass, dust mite, cockroach, fusarium) | ICS, LABA, LAMA | CRSwNP | Yes | 67 | 2622 | 1.1 | benralizumab | 27 | 5 |
| 2 | 47 | F | Black | Never | Yes (tree, grass, cockroach, cat, dog, fusarium, helminthosporium, epicoccum, aspergillus) | ICS, LABA, LAMA, LTRA | CRSwNP (AERD) | Yes | 49 | 345 | 0.1 | dupilumab | 11 | 5 |
| 3 | 76 | F | Black | Never | Yes (ragweed, dust mite, cockroach) | ICS, LABA, LAMA. LTRA | No | Yes | 28 | 12 | 0 | dupilumab | 1 | Excluded (<3months of biologic) |
| 4 | 51 | M | Caucasian | Never | Yes (tree, dust mite, cat, dog, alternaría, fusarium, helminthosporium, pénicillium, hormodendrum, aspergillus) | ICS, LABA | No | Yes | 57 | 357 | 0.05 | dupilumab | 7 | 4 |
| 5 | 58 | M | Declined | Former | Yes (tree, grass, ragweed, dust mite, cockroach, cat, dog, mouse, pénicillium, aspergillus) | ICS, LABA | CRSsNP | Yes | 23 | 1872 | 0.4 | benralizumab + omalizumab | 1* | Excluded (<3months of biologic) |
| 6 | 65 | F | Caucasian | Never | Not performed | ICS, LTRA | CRSsNP | Yes | 64 | 7.8 | 0.8 | dupilumab | 4 | 5 |
| 7 | 54 | F | Hispanic | Never | Yes (dust mite) | ICS, LABA LAMA. LTRA | No | Yes | 44 | 83 | 0.3 | benralizumab | 9 | 4 |
| 8 | 57 | F | Caucasian | Never | Yes (tree, grass, ragweed, dust mite, cat, dog, aspergillus) | ICS, LABA, LTRA | CRSsNP | Yes | 57 | 11.5 | 0 | benralizumab | 22 | 3 |
| 9 | 73 | F | Caucasian | Former | No (skin test negative) | ICS, LABA | No | Yes | 100 | 43.7 | 1.5 | reslizumab | 33 | 4 |
| 10 | 49 | F | Caucasian | Never | Yes (grass, ragweed, dust mite, cat, dog, alternaría, aspergillus) | ICS, LABA. LTRA | CRSwNP | Yes | 79 | 1144 | 0.8 | benralizumab + omalizumab | 23** | 4 |
| 11 | 57 | M | Declined | Former | Yes (aspergillus) | ICS, LABA, LTRA | CRSwNP (AERD) | Yes | 65 | 381 | 0.3 | reslizumab | 28 | 5 |
| 12 | 81 | M | Caucasian | Former | Yes (tree, ragweed, cat, dog, pénicillium, alternaría, helminthosporium, aspergillus) | ICS, LABA, LAMA | No | Yes | 51 | 43 | 0.1 | dupilumab + omalizumab | 6*** | 5 |
F: female, M: male
ICS: inhaled corticosteroid, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, LTRA: leukotriene receptor antagonists
CRS: chronic rhinosinusitis, CRSwNP: chronic rhinosinusitis with nasal polyps, CRSsNP: chronic rhinosinusitis without nasal polyps, AERD: aspirin exacerbated respiratory disease
FEV: forced expiratory volume, AEC: absolute eosinophil count
⇞
: 1= significantly worse, 2= somewhat worse, 3= same, 4= somewhat improved, 5= significantly improved
*
omalizumab: 26 months, benralizumab: 1 month,
**
omalizumab: 13.9 years, benralizumab: 23 months,
***
omalizumab: 4 years, dupilumab: 6 months